Ascendis Pharma FY 2025 Results: More Than A Takeover Story

2026-02-12 07:33:45 ET

Thesis

Over the past couple of month we've seen Ascendis Pharma ( ASND ) shares move higher due to some speculative takeover news. Back in January, shares saw a 7.5% jump after traders again circulated fresh takeover chatter tied to a Betaville uncooked alert. They suggested that a Switzerland-based pharmaceutical company and another European firm were weighing up a potential bid for the company. If you remember, this followed a very similar speculation back in December, when Betaville first flagged that Ascendis may have drawn some kind of acquisition interest. The result has been some short-lived rallies in the stock price, but overall, no such takeover has happened. In fact, when I last covered the stock back in December, I gave my take on who would be most interested in acquiring the company should we see a takeover. Since then, the stock price has remained relatively flat in both instances; the reports were based on market rumour. So whilst I don't rule out the possibility of a takeover sometime in 2026, I think investors should be cautious of buying solely on that speculation. We should rather evaluate Ascendis based on their latest earnings, which actually show much improved growth, especially from Yorvipath, which now seems to lead the way in terms of revenue....

Read the full article on Seeking Alpha

For further details see: